Research graph
References from Immunosuppression for adult steroid-dependent or frequently relapsing nephrotic syndrome: A systematic review and meta-analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
The nephrotic syndrome
10.1016/s0031-3955(16)32565-2 · 1971 · External reference
Controlled trial of prednisone in adult patients with the nephrotic syndrome
10.1136/bmj.3.5720.421 · 1970 · External reference
Adult-onset minimal change nephrotic syndrome: a long-term follow-up
10.1038/ki.1986.130 · 1986 · External reference
Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse. American journal of kidney diseases: the official journal of the
10.1016/s0272-6386(12)80353-2 · 1991 · External reference
Long-term outcome of adult-onset minimal-change nephropathy
10.1093/oxfordjournals.ndt.a027136 · 1996 · External reference
Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. American journal of kidney diseases: the official journal of the
10.1053/ajkd.2002.31400 · 2002 · External reference
Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses. Nephrology, dialysis, transplantation: official publication of the
2003 · External reference
The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome.
10.3389/fped.2015.00078 · 2015 · External reference
Treatment-Associated Side Effects in Patients with Steroid-Dependent Nephrotic Syndrome.
2022 · External reference
Management of Adult Minimal Change Disease. Clinical journal of the
10.2215/cjn.01920219 · 2019 · External reference
Optimal management of primary focal segmental glomerulosclerosis in adults
10.2147/ijnrd.s126844 · 2017 · External reference
History of Nephrotic Syndrome and Evolution of its Treatment.
2016 · External reference
Long-term assessment of cyclophosphamide therapy for nephrosis in children
10.1016/s0140-6736(74)92073-x · 1974 · External reference
Remission of idiopathic nephrotic syndrome after treatment with cyclosporin A
10.1136/bmj.292.6523.789 · 1986 · External reference
Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up.
10.1093/ndt/17.4.655 · 2002 · External reference
Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome.
10.1093/ndt/12.11.2433 · 1997 · External reference
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood
10.1016/0140-6736(90)90471-g · 1990 · External reference
Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil
10.1007/s004670050047 · 2000 · External reference
Rituximab in patients with the steroid-resistant nephrotic syndrome
10.1056/nejmc063706 · 2007 · External reference
Immunosuppressive Agent Options for Primary Nephrotic Syndrome: A Review of Network Meta-Analyses and Cost-Effectiveness Analysis.
10.3390/medicina59030601 · 2023 · External reference
Efficacy and acceptability of immunosuppressive agents for pediatric frequently-relapsing and steroid-dependent nephrotic syndrome: A network meta-analysis of randomized controlled trials
10.1097/md.0000000000015927 · 2019 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · 2021 · External reference
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.
2021 · External reference
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
10.1136/bmj.i4919 · 2016 · External reference
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
10.1136/bmj.39489.470347.ad · 2008 · External reference
Clinical profile and outcomes of steroid-dependent nephrotic syndrome in adults: A single-center experience.
2019 · External reference
Rituximab for minimal change disease in adults: long-term follow-up
10.1093/ndt/gft312 · 2014 · External reference
Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome
10.1093/ckj/sfy067 · 2018 · External reference
Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain
10.1007/s40259-017-0221-x · 2017 · External reference
Efficacy of low-dose rituximab in minimal change disease and prevention of relapse.
10.1186/s12882-023-03092-7 · 2023 · External reference
Rituximab in treatment of collapsing FSGS-A case series
10.1111/nep.13757 · 2021 · External reference
Cyclosporine therapy in steroid-dependent or steroid-resistant idiopathic focal and segmental glomerulosclerosis
10.4103/1319-2442.190864 · 2016 · External reference
Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease
10.1093/ndt/gfaa133 · 2021 · External reference
Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study
10.1007/s10157-018-1630-y · 2019 · External reference
Minimal-change disease in adolescents and adults: Epidemiology and therapeutic response
10.1093/ckj/sft063 · 2013 · External reference
Rituximab in minimal change disease
2018 · External reference
The evolving role of rituximab in adult minimal change glomerulopathy.
10.1159/000464475 · 2017 · External reference
A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood.
10.1186/s13104-015-1255-0 · 2015 · External reference
Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment.
10.1097/md.0000000000000300 · 2014 · External reference
Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
10.1093/ndt/gfu209 · 2014 · External reference
Leflunomide therapy for adult patients with steroid-dependent minimal change disease or primary focal segmental glomerulosclerosis
10.1097/cm9.0000000000001855 · 2022 · External reference
Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome
10.1007/s10157-015-1139-6 · 2016 · External reference
Rituximab is an efficient and safe treatment in adults with steroiddependent minimal change disease
10.1038/ki.2012.444 · 2013 · External reference
Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis.
10.18632/oncotarget.21833 · 2017 · External reference
Chronic nephrotoxicity limits successful use of Tacrolimus in the management of adult steroid-dependent minimal change disease
10.1111/nep.12392 · 2015 · External reference
Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults.
10.1093/ndt/gfs515 · 2013 · External reference
Efficacy and safety of single dose rituximab in steroid-dependent or frequently relapsing minimal change disease in a Chinese medical center
2021 · External reference
Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome
10.1093/ndt/gfm637 · 2008 · External reference
Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy
10.1111/nep.13554 · 2019 · External reference
Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome
10.1093/ckj/sfx035 · 2017 · External reference
Adult minimal-change disease: clinical characteristics, treatment, and outcomes
10.2215/cjn.03531006 · 2007 · External reference
Rituximab in maintaining remission in adults with podocytopathy
10.1111/nep.13717 · 2020 · External reference
Cyclosporine therapy in primary steroid-dependent and steroid-resistant focal segmental glomerulosclerosis in adults
2023 · External reference
Testing for Funnel Plot Asymmetry.
External reference
Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence.
10.1186/s12874-021-01381-z · 2021 · External reference
How should meta-regression analyses be undertaken and interpreted?
10.1002/sim.1187 · 2002 · External reference
The lack of statistical power of subgroup analyses in meta-analyses: a cautionary note.
10.1017/s2045796021000664 · 2021 · External reference
Reliability of adverse symptom event reporting by clinicians
10.1007/s11136-011-0031-4 · 2012 · External reference
Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis.
10.1093/ckj/sfaa191 · 2020 · External reference
Efficacy and acceptability of immunosuppressive agents for pediatric frequently-relapsing and steroid-dependent nephrotic syndrome: A network meta-analysis of randomized controlled trials
10.1097/md.0000000000015927 · 2019 · External reference
Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities
10.1186/s13643-015-0133-0 · 2015 · External reference
Interventions for minimal change disease in adults with nephrotic syndrome.
2022 · External reference
Interventions for focal segmental glomerulosclerosis in adults.
2022 · External reference
